Smartphone app aims to boost Well-Being after colorectal cancer

NCT ID NCT07158671

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This trial tests whether a mobile health (mHealth) program can improve quality of life for colorectal cancer survivors who have finished active treatment. About 210 Vietnamese-speaking adults will either use the app daily and receive biweekly phone calls for 3 months, or get usual care. The study measures changes in distress, depression, anxiety, fatigue, and bowel function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

mHealth survivorship program (mobile app and biweekly phone consultations)

What this could lead to

If it works, this could offer a simple, scalable way to help colorectal cancer survivors feel better emotionally and physically after treatment.

What could go wrong

This is a small, early-stage trial with no blinding, so results may be influenced by participants' expectations. The program requires daily app use, which may be hard for some to maintain.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER (DIAGNOSIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••